ViraTherapeutics GmbH

Boehringer Ingelheim GmbH is the latest pharmaceutical company to identify receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a viable target to treat cancer by splashing out €1.18bn to acquir

In an interview with Scrip , Boehringer Ingelheim International GmbH ’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focus

AstraZeneca PLC and immunotherapy specialist Transgene SA are to work together to develop armed oncolytic vaccinia virus candidates. The companies announced on 2 May that they have signed a deal to

Boehringer Ingelheim GMBH prides itself on early-stage deal making but in some cases the groundwork has been done years in advance by the German company's venture capital arm. "Our goal is to look at